Abstract
Purpose
To report a case where intravitreal bevacizumab injection was an effective treatment for diabetic papillopathy in a type 2 diabetic patient.
Case summary
A 47-year-old male with a 10-year history of diabetes mellitus type 2 presented to our clinic for evaluation of diabetic retinopathy. There were no subjective symptoms including blurred vision or visual defect, and best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/30 in the left eye. Fundus examination showed hyperemic optic disc swelling with telangiectatic new vessels, and fluorescein angiography leakage from the optic disc with neovascularization. The patient underwent fractionated panretinal photocoagulation. Ten days later, he complained of painless blurred vision with significant optic nerve head swelling and BCVA was 20/80 in the left eye. Intravitreal bevacizumab injection was ad-ministered, optic disc swelling was significantly decreased and BCVA improved to 20/30 after two months.
References
1. Lubow M, Makley TA Jr. Pseudopapilledema of juvenile diabetes mellitus. Arch Ophthalmol. 1971; 85:417–22.
3. Regillo CD, Brown GC, Savino PJ. . Diabetic papillopathy. Patient characteristics and fundus findinga. Arch Ophthalmol. 1995; 113:889–95.
4. Bayraktar Z, Alacali N, Bayraktar S. Diabetic papillopathy in type II diabetic patients. Retina. 2002; 22:752–8.
5. Heller SR, Tattersall RB. Optic disc swelling in young diabetic patients: a diagnostic dilemma. Diabetes Med. 1987; 4:260–4.
7. Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus non-diabetic patients. Ophthalmology. 2008; 115:1818–25.
8. Ostri C, Lund-Andersen H, Sander B. . Bilateral diabetic pap-illopathy and metabolic control. Ophthalmology. 2010; 117:2214–7.
9. Grunwald JE, Brucker AJ, Braunstein SN. . Strict metabolic control and retinal blood flow in diabetes mellitus. Br J Ophthalmol. 1994; 78:598–604.
10. Larsen M. Unilateral macular oedema secondary to retinal venous congestion without occlusion in patients with diabetes mellitus. Acta Ophthalmol Scand. 2005; 83:428–35.
11. Yang DW, Lee SH, Kim IT, Yun SU. Bilateral diabetic anterior is-chemic optic neuropathy. J Korean Ophthalmol Soc. 2004; 45:333–9.
12. Whittaker KW, Mehta JS, Tsaloumas MD. Bilateral diabetic pap-illopathy associated with optic disc neovascularisation. Eye (Lond). 2000; 14:(Pt 6). 914–5.
13. Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolonce acetonide for the management of diabetic papillopathy. Am J Ophthalmol. 2004; 137:1151–3.
14. Ornek K, Oğurel T.Intravitreal bevacizumab for diabetic papillo-pathy. J Ocul Pharmacol Ther. 2010; 26:217–8.
15. Al-Dhibi H, Khan AO. Response of diabetic papillopathy to intra-vitreal bevacizumab. Middle East Afr J Ophthalmol. 2011; 18:243–5.
16. Willerslev A, Munch IC, Larsen M. Resolution of diabetic papill-opathy after a single intravitreal injection of ranibizumab. Acta Ophthalmol. 2012; 90:e407–9.
17. Van Bruggen N, Thibodeaux H, Palmer JT. . VEGF antago-nism reduces edema formation and tissue damage after ischemia/ reperfusion injury in the mouse brain. J Clin Invest. 1999; 104:1613–20.